EXTENSION OF HELIX-II OF AN HIV-1-DIRECTED HAMMERHEAD RIBOZYME WITH LONG ANTISENSE FLANKS DOES NOT ALTER KINETIC-PARAMETERS IN-VITRO BUT CAUSES LOSS OF THE INHIBITORY POTENTIAL IN LIVING CELLS
M. Homann et al., EXTENSION OF HELIX-II OF AN HIV-1-DIRECTED HAMMERHEAD RIBOZYME WITH LONG ANTISENSE FLANKS DOES NOT ALTER KINETIC-PARAMETERS IN-VITRO BUT CAUSES LOSS OF THE INHIBITORY POTENTIAL IN LIVING CELLS, Nucleic acids research, 22(19), 1994, pp. 3951-3957
When designed to cleave a target RNA in trans, the hammerhead ribozyme
contains two antisense flanks which form helix I and helix III by pai
ring with the complementary target RNA. The sequences forming helix II
are contained on the ribozyme strand and represent a major structural
component of the hammerhead structure. In the case of an inhibitory 4
29 nucleotides long trans-ribozyme (2as-Rz12) which was directed again
st the 5'-leader/gag region of the human immunodeficiency virus type 1
(HIV-1), helix II was not pre-formed in the single-stranded molecule.
Thus, major structural changes are necessary before cleavage can occu
r. To study whether pre-formation of helix II in the non-paired 2as-Rz
12 RNA could influence the observed cleavage rate in vitro and its inh
ibitory activity on HIV-1 replication, we extended the 4 base pair hel
ix II of 2as-Rz12 to 6, 16, 21, and 22 base pairs respectively. Limite
d RNase cleavage reactions performed in vitro at 37 degrees C and at p
hysiological ion strength indicated that a helix II of the hammerhead
domain was pre-formed when its length was at least six base pairs. Thi
s modification neither affected the association rate with target RNA n
or the cleavage rate in vitro. In contrast to this, extension of helix
II led to a significantly decreased inhibition of HIV-1 replication i
n human cells. Together with the finding of others that shortening of
helix II to less than two base pairs reduces the catalytic activity in
vitro, this observation indicates that the length of helix II in the
naturally occurring RNAs with a hammerhead domain is already close or
identical to the optimal length for catalytic activity in vitro and in
vivo.